Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: A Danish cohort study

Journal of Viral Hepatitis

Volumn 16, Issue 9, 2009, Pages 659-665

  Hansen, N ^a   Obel, N ^b   Christensen, P B ^c   Krarup, H ^d   Laursen, A L ^e   Clausen, M R ^b   Lunding, S ^f   Moller A ^g   Schlichting, P ^h   Kromann Andersen, H ⁱ   Bukh, J ^a,j,k   Weis, Nina ^a   Feldager, Erik ^l   Hansen, Jeppe ^m   Krogsgaard, Kim ^a   Lindberg, Jens ⁿ   Nielsen, Henrik ^d   Nielsen, Jens Ole ^a   Schaffalitzky De Muckadell, Ove B ^c   Tage Jensen, Ulrik ^d   Utzon, Jan ^o   more..

^a Mental Health Center Glostrup   (Denmark)

^b Rigshospitalet   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f Department of Internal Medicine   (Denmark)

^g KOLDING HOSPITAL   (Denmark)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ Koege Hospital   (Denmark)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^l HVIDOVRE HOSPITAL   (Denmark)

^m FREDERIKSBERG HOSPITAL   (Denmark)

ⁿ HERNING HOSPITAL   (Denmark)

^o BISPEBJERG HOSPITAL   (Denmark)

more..

Author keywords

Antiviral therapy; Chronic hepatitis C; Cohort study; Genotype; Predictors; Treatment initiation

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENMARK; FEMALE; HELP SEEKING BEHAVIOR; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; PATIENT DECISION MAKING; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; DENMARK; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; RIBAVIRIN; YOUNG ADULT;

EID: 68949205214     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01126.x     Document Type: Article

References (22)

1. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferin alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006 3 : 47 52.
4. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002 36 (Suppl 1 S47 S56.
5. Yano M, Kumada H, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996 23 : 1334 1340.
6. Strader DB, Wright T, Thomas DL, Seef LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
7. Danmarks Statistik, 2008. Available at: http://www.dst.dk.
8. Department of Public Health. Hepatitisvejledningen af 2002. Denmark : Department of Public Health, 2002. Available at: http://www.sst.dk/publ/ publ2002/hepatitis/html/index.htm.
9. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996 24 : 289 293.
10. Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002 21 : 1129 1144.
11. Farrell GC. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statement on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007 22 : 615 633.
12. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injecting drug users: implications for treatment. Clin Infect Dis 2005 40 (suppl.5 263 269.
13. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virological response in hepatitis B and C. J Hepatol 2008 49 : 634 651.
14. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003 138 : 197 207.
15. Verruchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004 32 : 33 42.
16. Courneot M, Glibert A, Castel F et al. Management of hepatitis C in active drug users:experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004 28 : 533 539.
17. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injecting drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005 40 : 339 345.
18. Lettmeier B, Mühlberger N, Schwarzer R et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008 49 : 528 536.
19. Falck-Ytter Y, Kale H, Mullen K, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002 136 : 288 292.
20. Kanwal F, Hoang T, Spiegel BM et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007 46 : 1741 1749.
21. Duberg AS, Torner A, Davidsdottir L et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 2008 15 : 538 550.
22. Neal KR, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007 56 : 1098 1104.